Bertram CG, Gaut RM, Barrett JH, Randerson-Moor J, Whitaker L, Turner F, Bataille V, dos Santos Silva I, Swedlow AJ, Bishop DT, Newton Bishop JA. An assessment of a variant of the DNA repair gene XRCC3 as a possible nevus or melanoma susceptibility genotype. J Invest Dermatol 2004 122 (2):429-432
Newton Bishop JA, Nolan C, Turner F, McCabe M, Boxer C, Merion Thomas J, Coombes G, A'Hern RPA, Barrett JH. A quality of life study in high-risk (thickness >=or 2mm) cutaneous melanoma patients in a randomized trial of 1cm versus 3cm surgical excision margins. J Invest Dermatol Symp Proc 2004 Mar;9(2):152-9
Thomas JM, Newton Bishop JA, A'Hern R, Coombes G, Evans J, Cook M, Theaker J, Fallowfield M, Timmons M, O'Neill T, Ruka W, Bliss J, on behalf of the UK Melanoma Study Group. Excision margins in high-risk malignant melanoma. New Engl J Med 2004 Feb 19; 350(8):757-66
Bataille V, Winnett A, Sasieni P, Newton Bishop JA, Cuzick J Exposure to the sun and sunbeds and the risk of cutaneous melanoma in the UK: a case-control study. Eur J Cancer. 2004 Feb;40(30:429-35
Lens MB, Newton Bishop JA, Dawes M Surgical margins in cutaneous melanoma (2cm versus 5cm for lesions measuring less than 2.1mm thick). Cancer. 2004 Jan 15;100(2):433-4
Boyle P, Autier P, Bartelink H, Baselga J, Boffetta P, Burn J, Burns HJG, Christensen L, Denis L, Dicato M, Diehl V, Doll R, Franceschi S, Gillis CR, Gray N, Gricuite L, Hackshaw A, Kasler M, Kogevinas M, Kvinnsland S, La Vecchia C, Levi F, McVie JG, Maisonneuve P, Martin-Moreno J, Newton Bishop JA, Oleari F, Perrin P, Richards M, Ringborg U, Siracka E, Quinn M, Storm H, Tubiana M, Tursz T, Veronesi U, Wald N, Weber W, Zaridze DG, Zatonski W, zur Hausen H European code against cancer Third Version (2003) and scientific justification. Ann Oncol 2003 Jul;14(7):973-1005
Barrett JH, Gaut R, Wachsmuth R, Newton Bishop JA, Bishop DT Linkage and association analysis of nevus density and the region containing the melanoma gene CDKN2A in a study of UK twins. Br J Cancer 2003 88:1920-1924
Gillanders E, Juo S-HH, Holland EA, Jones M, Nancarrow D, Freas-Lutz D, Sood R, Park N, Faruque M, Markey C, Kefford RF, Palmer J, Bergman W, Bishop DT, Tucker MA, Bressac-de Paillerets B, Hansson J, Stark M, Gruis N, Newton Bishop J, Goldstein AM, Bailey-Wilson J, Mann GJ, Hayward N, Trent J, on behalf of the Melanoma Genetics Consortium Localization of a Novel Melanoma Susceptibility Locus to 1p22. Am J Hum Genet 73:301-13, 2003
Hoffmann K, Gambichler T, Rick A, Kreutz M, Ansch M, Grnendick T, Orlikov A, Gehlen G, Perotti R, Andreassi L, Newton Bishop J, Sarini J-P, Fischer T, Frosch PJ, Lindskov R, MacKie R, Nashan D, Sommer A, Neumann MHA, Ortonne J-P, Bahadoran P, Penas PF, Zoras U, Altmeyer P Diagnostic And Neuronal Analysis Of Skin cancer (DANAOS): a multi-center study for collection and capture aided analysis of data from pigmented skin lesions. Br J Dermatol 2003 Oct;149 (4):801-9
Stefoski Mikeljevic J, Johnston C, Adamson PJ, Wright A, Newton Bishop JA, Batman P, Neal RD, Forman D How complete has skin cancer registration been in the UK? A study from Yorkshire. Eur J Cancer Prev 2003 12:125-33
Bertram CG, Gaut RM, Barrett JH, Pinney E, Whitaker L, Turner F, Bataille V, Dos Santos Silva I, A JS, Bishop DT, Newton Bishop JA An assessment of the CDKN2A variant Ala148Thr as a nevus/melanoma susceptibility allele. J Invest Dermatol 2002 119:961-5
Bishop DT, Demenais F, Goldstein AM, Bergman W, Bishop JN, Bressac-de Paillerets B, Chompret A, Ghiorzo P, Gruis N, Hansson J, Harland M, Hayward N, Holland EA, Mann GJ, Mantelli M, Nancarrow D, Platz A, Tucker MA Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst 2002 94:894-903
Huot TJ, Rowe J, Harland M, Drayton S, Brookes S, Gooptu C, Purkis P, Fried M, Bataille V, Hara E, Newton-Bishop J, Peters G Biallelic mutations in p16(INK4a) confer resistance to Ras- and Ets-induced senescence in human diploid fibroblasts. Mol Cell Biol 2002 22:8135-43
Lens MB, Dawes M, Goodacre T, Bishop JA Excision margins in the treatment of primary cutaneous melanoma: a systematic review of randomized controlled trials comparing narrow vs wide excision. Arch Surg 2002 137:1101-5
Lens MB, Dawes M, Goodacre T, Newton-Bishop JA Elective lymph node dissection in patients with melanoma: systematic review and meta-analysis of randomized controlled trials. Arch Surg 2002 137:458-61
Lens MB, Dawes M, Newton-Bishop JA, Goodacre T Management of regional lymph nodes in patients with malignant melanoma: questionnaire survey of UK current practice. Br J Plast Surg 2002 55:372-5
Lens MB, Dawes M, Newton-Bishop JA, Goodacre T Tumour thickness as a predictor of occult lymph node metastases in patients with stage I and II melanoma undergoing sentinel lymph node biopsy. Br J Surg 2002 89:1223-7
Newton Bishop JA, Corrie PG, Evans J, Gore ME, Hall PN, Kirkham N, Roberts DL, Anstey AV, Barlow RJ, Cox NH Ambiguity in the UK guidelines for the management of cutaneous melanoma: a reply from authors. Br J Dermatol 2002:836-837
(This is not a PubMed citation)
Newton Bishop JA, Corrie PG, Evans J, Gore ME, Hall PN, Kirkham N, Roberts DL, Anstey AV, Barlow RJ, Cox NH High dose interferon, sentinel lymph node biopsy and the UK guidelines for cutaneous melanoma: reply from authors. Br J Dermatol 2002:834-835
(This is not a PubMed citation)
Newton Bishop JA, Corrie PG, Evans J, Gore ME, Hall PN, Kirkham N, Roberts DL, Anstey AV, Barlow RJ, Cox NH Staging investigations and the UK guidelines for cutaneous melanoma: reply from authors. Br J Dermatol 2002:838
(This is not a PubMed citation)
Newton Bishop JA, Corrie PG, Evans J, Gore ME, Hall PN, Kirkham N, Roberts DL, Anstey AV, Barlow RJ, Cox NH UK guidelines for the management of cutaneous melanoma. Br J Plast Surg 2002 55:46-54
Roberts DL, Anstey AV, Barlow RJ, Cox NH, Newton Bishop JA, Corrie PG, Evans J, Gore ME, Hall PN, Kirkham N U.K. guidelines for the management of cutaneous melanoma. Br J Dermatol 2002 146:7-17
Harland M, Mistry S, Bishop DT, Bishop JA A deep intronic mutation in CDKN2A is associated with disease in a subset of melanoma pedigrees. Hum Mol Genet 2001 10:2679-86
Randerson-Moor JA, Harland M, Williams S, Cuthbert-Heavens D, Sheridan E, Aveyard J, Sibley K, Whitaker L, Knowles M, Bishop JN, Bishop DT A germline deletion of p14(ARF) but not CDKN2A in a melanoma-neural system tumour syndrome family. Hum Mol Genet 2001 10:55-62
Wachsmuth RC, Gaut RM, Barrett JH, Saunders CL, Randerson-Moor JA, Eldridge A, Martin NG, Bishop DT, Newton Bishop JA Heritability and gene-environment interactions for melanocytic nevus density examined in a U.K. adolescent twin study. J Invest Dermatol 2001 117:348-52
Harland M, Holland EA, Ghiorzo P, Mantelli M, Bianchi-Scarra G, Goldstein AM, Tucker MA, Ponder BA, Mann GJ, Bishop DT, Newton Bishop J Mutation screening of the CDKN2A promoter in melanoma families. Genes Chrom Cancer 2000 28:45-57
McWhirter JM, Collins M, Bryant I, Wetton NM, Newton Bishop J Evaluating 'Safe in the Sun', a curriculum programme for primary schools. Health Educ Res 2000 15:203-17
Newton Bishop J, Harland M, Wachsmuth R, Pinney E, Bataille V, Whitaker L, Cuzick J, Bishop D Genotype/phenotype and penetrance studies in melanoma families with germline CDKN2A mutations. J Invest Dermatol 2000 114:28-33
Newton Bishop JA, Bradburn M, Bergman W, Osterlind A, Pinney E, Rosdahl I, Scerri L, Weichenthal M, Mant D, Breitbart E, Karlsson P, Altman D Teaching non-specialist health care professionals how to identify the atypical mole syndrome phenotype: a multinational study. Br J Dermatol 2000 142:331-337
Kefford RF, Newton Bishop JA, Bergman W, Tucker MA Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma: A consensus statement of the Melanoma Genetics Consortium. J Clin Oncol 1999 17:3245-51
Kupsch JM, Tidman NH, Kang NV, Truman H, Hamilton S, Patel N, Newton Bishop JA, Leigh IM, Crowe JS Isolation of human tumor-specific antibodies by selection of an antibody phage library on melanoma cells. Clin Cancer Res 1999 5:925-31
Thomas MD, Clough K, Melamed MD, Stevenson FK, Chapman CJ, Spellerberg MB, Potter KN, Newton-Bishop JA, Gregson N, Dawson K A human monoclonal antibody encoded by the V4-34 gene segment recognises melanoma-associated ganglioside via CDR3 and FWR1. Hum Antibodies 1999 9:95-106
Bataille V, Grulich A, Sasieni P, Swerdlow A, Newton Bishop J, McCarthy W, Hersey P, Cuzick J The association between naevi and melanoma in populations with different levels of sun exposure: a joint case-control study of melanoma in the UK and Australia. Br J Cancer 1998 77:505-10
Bataille V, Sasieni P, Grulich A, Swerdlow A, McCarthy W, Hersey P, Newton Bishop JA, Cuzick J Solar keratoses: a risk factor for melanoma but negative association with melanocytic naevi. Int J Cancer 1998 78:8-12
Marshall JF, Rutherford DC, Happerfield L, Hanby A, McCartney AC, Newton-Bishop J, Hart IR Comparative analysis of integrins in vitro and in vivo in uveal and cutaneous melanomas. Br J Cancer 1998 77:522-9
Pollock PM, Spurr N, Bishop T, Newton-Bishop J, Gruis N, van der Velden PA, Goldstein AM, Tucker MA, Foulkes WD, Barnhill R, Haber D, Fountain J, Hayward NK Haplotype analysis of two recurrent CDKN2A mutations in 10 melanoma families: evidence for common founders and independent mutations. Hum Mutat 1998 11:424-31
Wachsmuth RC, Newton Bishop JA, Gaut RM, Barrett JH, Bishop DT (2001) The influence of genes and environment on nevus density in sun-exposed and sun-protected sites: a study of UK adolescent twins. Paper presented at IGES
22. Randerson-Moor, J.A., et al.,
Epidermal Growth Factor (EGF) 5’UTR Variant A61G Is Not Associated with Increased Risk of Cutaneous Melanoma.
J Invest Dermatol, 2004: p. In press.
